China Energy Storage Technology Development Limited — Capital/Financing Update 2021

Jul 8, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

VOLUNTARY ANNOUNCEMENT ENTERING INTO THE STRATEGIC INVESTMENT AND COOPERATION MEMORANDUM OF UNDERSTANDING

This announcement is made by Link-Asia International MedTech Group Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) on a voluntary basis to provide the shareholders (the ‘‘Shareholders’’) and potential investors of the Company with updated information in relation to the latest business development of the Group.

THE STRATEGIC INVESTMENT AND COOPERATION MEMORANDUM OF UNDERSTANDING

The board of directors of the Company (the ‘‘Board’’) is pleased to announce that, on 8 July 2021 (after trading hours), the Company entered into a strategic investment and cooperation memorandum of understanding (the ‘‘MOU’’) with Lux Aeterna Capital Limited (‘‘Lux Capital’’).

According to the MOU, Lux Capital intends to strategically invest in and cooperate with the Company, with an investment/cooperation scale of around HK$300 million. The investment/ cooperation model includes, but not limited to, subscription for shares and bonds of the Company by Lux Capital, provision of financing support for the Company’s investments in M&A projects, or joint investment in the Company’s projects. The investment/cooperation will be implemented in phases, and the final actual investment/cooperation amount will be subject to the formal investment/cooperation agreement to be signed by both parties. Unless otherwise agreed by both parties, the proportion of Lux Capital’s equity investment in the Company is limited to the extent that it does not trigger the mandatory takeover offer under ‘‘The Codes on Takeovers and Mergers and Share Buy-backs’’ published by Securities and Futures Commission of Hong Kong (‘‘SFC’’).

The MOU is valid for one year (the ‘‘validity period’’). During the validity period, Lux Capital will conduct due diligence on the Company. Upon completion of the due diligence and approval by the decision-making bodies of both parties, a formal investment/cooperation agreement will be signed between both parties.

– 1 –

The Board is of the view that once the strategic investment and in-depth cooperation of Lux Capital materializes, it will help the Company to accelerate the development of assisted reproduction business, thus improve the financial performance of the Company.

INFORMATION ABOUT LUX CAPITAL

Lux Capital is a company incorporated in Hong Kong with limited liability. As advised by Lux Capital, it is licensed by SFC to carry out Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (asset management) regulated activity under the Securities and Futures Ordinance, and is a professional asset management institute with total assets under management/advice of approximately HK$3 billion. The core management team of Lux Capital are from Morgan Stanley, Deutsche Bank and Goldman Sachs etc., with rich experience in global investment and asset management.

To the best knowledge, information and belief of the directors of the Company having made all reasonable enquiries, Lux Capital and its ultimate beneficial owner are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’)) as at the date of this announcement.

GENERAL INFORMATION

The MOU is a document of intent between Lux Capital and the Company. Except for validity period, confidentiality, termination, legal effect and applicable legal provisions, other provisions are not legally binding.

The Board wishes to emphasize that as at the date of this announcement, the Company has not entered into any legally binding agreement in relation to the strategic investment and cooperation matters with Lux Capital. The strategic investment/cooperation, if materialised, may constitute a notifiable transaction for the Company under the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and potential investors of the Company should note that the strategic investment in/cooperation with the Company by Lux Capital may or may not proceed, and are advised to exercise caution when dealing in the shares.

By order of the Board Link-Asia International MedTech Group Limited Lin Dailian Chairman and executive Director

Hong Kong, 8 July 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.

– 2 –